New Triple-Threat attack on rare bile duct cancer
NCT ID NCT06501625
Summary
This study is testing whether adding two newer drugs (ivosidenib and durvalumab) to standard chemotherapy works better for people with advanced bile duct cancer that has a specific genetic change called IDH1 mutation. The trial will first check if the combination is safe, then see if it helps shrink tumors. About 52 people with this specific type of cancer who haven't had prior treatment for their advanced disease can participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, 3004, Australia
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, 05505, South Korea
-
CIONC
NOT_YET_RECRUITINGCuritiba, 80810050, Brazil
-
Cha Bundang Medical Center
RECRUITINGSeongnam, 13496, South Korea
-
Charite Universitatsmedizin
RECRUITINGBerlin, 13353, Germany
-
Chu Montpellier-Hopital Saint-Eloi
RECRUITINGMontpellier, 34295, France
-
Duke University
RECRUITINGDurham, North Carolina, 27708, United States
-
Gibbs Cancer Center
NOT_YET_RECRUITINGSpartanburg, South Carolina, 29303, United States
-
H. 12 de Octubre
RECRUITINGMadrid, 28040, Spain
-
H. Valle de Hebron
RECRUITINGBarcelona, 8035, Spain
-
Hospital Clinic de Barcelona
NOT_YET_RECRUITINGBarcelona, Spain
-
Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario Gregorio Marañón
RECRUITINGMadrid, 28007, Spain
-
Hospital de Amor - Barretos
RECRUITINGBarretos, 14784400, Brazil
-
Hôpital Beaujon
RECRUITINGClichy, 92210, France
-
Institut Bergonie
RECRUITINGBordeaux, 33076, France
-
Instituto Dor de Pesquisa E Ensino Sp
RECRUITINGSão Paulo, 4543000, Brazil
-
Kanagawa Cancer Center
RECRUITINGYokohama, 241-8515, Japan
-
Kyoto University Hospital
RECRUITINGKyoto, 606-8507, Japan
-
Medizinische Hochschule Hannover Oe 6810
RECRUITINGHanover, 30625, Germany
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
National Cancer Center Hospital
RECRUITINGChūōku, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
Northwestern Medicine
RECRUITINGChicago, Illinois, 60611, United States
-
Oncoclinicas Mg
NOT_YET_RECRUITINGBelo Horizonte, 303600680, Brazil
-
Princess Margaret Cancer Centre
RECRUITINGToronto, M5G 2C4, Canada
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 3080, South Korea
-
Seoul St. Mary'S Hospital
RECRUITINGSeoul, 6591, South Korea
-
Severance
RECRUITINGSeoul, 3722, South Korea
-
Tennesse Oncology - Elliston Place Plaza
RECRUITINGNashville, Tennessee, 37203, United States
-
The University of Texas Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Universitären Centrums Für Tumorerkrankungen (Uct) Der J.W. Goethe-Universität Frankfurt
RECRUITINGFrankfurt, 60488, Germany
-
Universitätsklinikum Düsseldorf
RECRUITINGDüsseldorf, 40225, Germany
-
Universitätsklinikum Ulm
RECRUITINGUlm, 89081, Germany
-
Usc Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.